PRESS RELEASE published on 12/04/2024 at 19:50, 1 year 9 months ago Inside Information / Other news releases TME Pharma announces corporate strategy update with upcoming €2.6 million financing aimed at further developing therapies for cancer treatment through public offer open to shareholders. CEO Mangasarian highlights strategic goals and plans Financing Cancer Treatment Public Offer Corporate Strategy TME Pharma
BRIEF published on 11/23/2024 at 10:59, 1 year 9 months ago TME Pharma présente ses résultats sur NOX-A12 dans le glioblastome Thérapie Contre Le Cancer Glioblastome NOX-A12 Inhibition Du Point De Contrôle Immunitaire Microenvironnement Tumoral
BRIEF published on 11/23/2024 at 10:59, 1 year 9 months ago TME Pharma Presents Findings on NOX-A12 in Glioblastoma Cancer Therapy Glioblastoma NOX-A12 Immune Checkpoint Inhibition Tumor Microenvironment
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 9 months ago Informations privilégiées / Autres communiqués TME Pharma annonce la présentation d'un poster par le National Cancer Institute américain sur l'inhibition de CXCL12 par NOX-A12 dans le glioblastome à la réunion annuelle du SNO 2024 Glioblastome TME Pharma NOX-A12 National Cancer Institute Inhibition
PRESS RELEASE published on 11/23/2024 at 10:54, 1 year 9 months ago Inside Information / Other news releases TME Pharma presents poster on NOX-A12 inhibition of CXCL12 in glioblastoma at 2024 SNO Annual Meeting, demonstrating enhanced anti-tumor immune responses in brain cancer models Glioblastoma TME Pharma NOX-A12 CXCL12 Inhibition SNO Annual Meeting
BRIEF published on 08/12/2024 at 19:05, 2 years ago TME Pharma augmente les ressources allouées au contrat de liquidité Contrat De Liquidité Répartition Des Actions Décision De L'AMF TME Pharma Investir Dans Des Titres
BRIEF published on 08/12/2024 at 19:05, 2 years ago TME Pharma Increases Allocated Resources for Liquidity Contract Liquidity Contract INVEST SECURITIES AMF Decision TME Pharma Share Allocation
PRESS RELEASE published on 08/12/2024 at 19:00, 2 years ago Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité TME Pharma augmente les ressources allouées au contrat de liquidité avec Invest Securities pour soutenir trésorerie et titres. Détails disponibles post-augmentation Contrat Liquidité INVEST SECURITIES Ressources TME Pharma
PRESS RELEASE published on 08/12/2024 at 19:00, 2 years ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract TME Pharma increases resources for liquidity contract with Invest Securities to support cash balance and securities. Details of the update provided in accordance with AMF regulations Liquidity Contract Biotechnology INVEST SECURITIES AMF Regulations TME Pharma
Published on 09/12/2026 at 02:35, 13 hours 50 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 17 hours 25 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 18 hours 20 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 19 hours ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 23 hours 25 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 8 hours 55 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 18 hours 10 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 18 hours 15 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 20 hours 40 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 22 hours 10 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 9 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 20 hours ago Availability of the 2026 Interim Financial Report
